Drug General Information
Drug ID
D00LNW
Former ID
DIB005469
Drug Name
KPT-330
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 2 [524584]
Company
Karyopharm therapeutics
Structure
Download
2D MOL

3D MOL

Formula
C17H11F6N7O
Canonical SMILES
C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)<br />F)C(F)(F)F
InChI
1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-
InChIKey
DEVSOMFAQLZNKR-RJRFIUFISA-N
PubChem Compound ID
PubChem Substance ID
Drug Resistance Mutation (DRM)
DRM DRM Info
Target and Pathway
Target(s) Exportin-1 Target Info Inhibitor [544432]
KEGG Pathway Ribosome biogenesis in eukaryotes
RNA transport
Influenza A
HTLV-I infection
Epstein-Barr virus infection
Pathway Interaction Database Signaling events mediated by HDAC Class II
Canonical NF-kappaB pathway
Integrin-linked kinase signaling
Signaling events mediated by HDAC Class I
Role of Calcineurin-dependent NFAT signaling in lymphocytes
FoxO family signaling
Sumoylation by RanBP2 regulates transcriptional repression
Hedgehog signaling events mediated by Gli proteins
Regulation of nuclear beta catenin signaling and target gene transcription
Reactome Separation of Sister Chromatids
Resolution of Sister Chromatid Cohesion
Deactivation of the beta-catenin transactivating complex
HuR (ELAVL1) binds and stabilizes mRNA
RHO GTPases Activate Formins
Mitotic Prometaphase
Cyclin A/B1 associated events during G2/M transition
WikiPathways Mitotic Metaphase and Anaphase
Signaling by TGF-beta Receptor Complex
Regulation of mRNA Stability by Proteins that Bind AU-rich Elements
Host Interactions of HIV factors
Influenza Life Cycle
HIV Life Cycle
Mitotic Prometaphase
Mitotic G2-G2/M phases
References
Ref 524584ClinicalTrials.gov (NCT02025985) Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies. U.S. National Institutes of Health.
Ref 544432Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.